[go: up one dir, main page]

WO2004052350A3 - Methode de traitement de troubles moteurs a l'aide de derives de l'acide barbiturique - Google Patents

Methode de traitement de troubles moteurs a l'aide de derives de l'acide barbiturique Download PDF

Info

Publication number
WO2004052350A3
WO2004052350A3 PCT/US2003/039530 US0339530W WO2004052350A3 WO 2004052350 A3 WO2004052350 A3 WO 2004052350A3 US 0339530 W US0339530 W US 0339530W WO 2004052350 A3 WO2004052350 A3 WO 2004052350A3
Authority
WO
WIPO (PCT)
Prior art keywords
lower alkyl
movement disorders
acid derivatives
treating movement
barbituric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/039530
Other languages
English (en)
Other versions
WO2004052350A2 (fr
Inventor
Daniel Aaron Moros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceuticals Ireland Ltd
Original Assignee
Taro Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA05006271A priority Critical patent/MXPA05006271A/es
Priority to EP03812970A priority patent/EP1569627B1/fr
Priority to CA2505335A priority patent/CA2505335C/fr
Priority to BR0317289-9A priority patent/BR0317289A/pt
Priority to AU2003302897A priority patent/AU2003302897C1/en
Priority to DE60324703T priority patent/DE60324703D1/de
Application filed by Taro Pharmaceuticals Ireland Ltd filed Critical Taro Pharmaceuticals Ireland Ltd
Priority to JP2004558727A priority patent/JP4739760B2/ja
Publication of WO2004052350A2 publication Critical patent/WO2004052350A2/fr
Publication of WO2004052350A3 publication Critical patent/WO2004052350A3/fr
Priority to IL168853A priority patent/IL168853A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une méthode de traitement de troubles moteurs consistant à administrer à un humain ou à un animal nécessitant un tel traitement une dose thérapeutique d'au moins un composé représenté par la formule générale (I) dans laquelle R3 et R4 désignent chacun indépendamment un élément sélectionné dans le groupe comprenant un alkyle inférieur, un phényle et un phényle substitué par un alkyle inférieure, et R1 et R2 désignent chacun indépendamment soit un atome d'hydrogène, soit un radical représenté par la formule générale (II) dans laquelle R5 et R6 désignent chacun indépendamment un élément sélectionné dans le groupe comprenant un atome d'hydrogène, un alkyle inférieur, un phényle et un phényle substitué par un alkyle inférieur. L'invention concerne également des sels de qualité pharmaceutique, des promédicaments et des métabolites de ce composé.
PCT/US2003/039530 2002-12-11 2003-12-11 Methode de traitement de troubles moteurs a l'aide de derives de l'acide barbiturique Ceased WO2004052350A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP03812970A EP1569627B1 (fr) 2002-12-11 2003-12-11 Methode de traitement de troubles moteurs a l'aide de derives de l'acide barbiturique
CA2505335A CA2505335C (fr) 2002-12-11 2003-12-11 Methode de traitement de troubles moteurs a l'aide de derives de l'acide barbiturique
BR0317289-9A BR0317289A (pt) 2002-12-11 2003-12-11 Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico
AU2003302897A AU2003302897C1 (en) 2002-12-11 2003-12-11 Method of treating movement disorders using barbituric acid derivatives
DE60324703T DE60324703D1 (de) 2002-12-11 2003-12-11 Barbitursäure derivaten.
MXPA05006271A MXPA05006271A (es) 2002-12-11 2003-12-11 Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico.
JP2004558727A JP4739760B2 (ja) 2002-12-11 2003-12-11 バルビツール酸誘導体を使用する運動障害の治療方法
IL168853A IL168853A (en) 2002-12-11 2005-05-29 Use of barbituric acid derivatives in the preparation of medicinal preparations for the treatment of movement disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43247002P 2002-12-11 2002-12-11
US60/432,470 2002-12-11

Publications (2)

Publication Number Publication Date
WO2004052350A2 WO2004052350A2 (fr) 2004-06-24
WO2004052350A3 true WO2004052350A3 (fr) 2004-09-23

Family

ID=32507936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/039530 Ceased WO2004052350A2 (fr) 2002-12-11 2003-12-11 Methode de traitement de troubles moteurs a l'aide de derives de l'acide barbiturique

Country Status (17)

Country Link
US (3) US7166610B2 (fr)
EP (2) EP1569627B1 (fr)
JP (1) JP4739760B2 (fr)
CN (2) CN100502871C (fr)
AR (1) AR042444A1 (fr)
AT (1) ATE413867T1 (fr)
AU (2) AU2003302897C1 (fr)
BR (1) BR0317289A (fr)
CA (1) CA2505335C (fr)
CL (1) CL2003002588A1 (fr)
DE (1) DE60324703D1 (fr)
ES (1) ES2315569T3 (fr)
IL (1) IL168853A (fr)
MX (1) MXPA05006271A (fr)
PT (1) PT1569627E (fr)
TW (2) TWI334780B (fr)
WO (1) WO2004052350A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
TWI334780B (en) 2002-12-11 2010-12-21 Taro Pharmaceuticals Ireland Ltd Method of treating movement disorders using barbituric acid derivatives
CA2572797A1 (fr) * 2004-07-02 2006-01-12 Daniella Gutman Procede de preparation d'acide 1-methoxymethyl-5,5-diphenylbarbiturique
EP1625848A1 (fr) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition et procédé pour améliorer l'administration de l'acide 5,5-diphénylbarbiturique
EP2081576A4 (fr) * 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame Procédé d'amélioration de la biodisponibilité pour les barbituriques non sédatifs
WO2013038427A1 (fr) * 2011-09-12 2013-03-21 Council Of Scientific & Industrial Research Composés de β-dicarbonyle arylés et leur procédé de préparation
IT201700059814A1 (it) * 2017-05-31 2018-12-01 Antonio Costantini Vitamina b1 in alte dosi per uso nel trattamento medico di alcune malattie neurodegenerative sporadiche , di origine genetica e delle cefalee primarie
JP7357432B2 (ja) 2017-10-10 2023-10-06 信越化学工業株式会社 Ｅｕｖ用ペリクルフレーム、ペリクル、ペリクル付露光原版、露光方法、及び半導体の製造方法
EP4422756A1 (fr) * 2021-10-29 2024-09-04 Gilead Sciences, Inc. Composés cd73

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930006A (en) * 1963-04-30 1975-12-30 Aspro Nicholas Ltd Antiparkinsonism compositions and method
WO2001039779A1 (fr) * 1999-12-01 2001-06-07 Ucb, S.A. Derive de pyrrolidine acetamide seul ou combine pour traiter des affections du snc

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1960170A (en) 1934-05-22 Cc - phenylethyl - n -
US2119701A (en) 1934-06-29 1938-06-07 Winthrop Chem Co Inc Alkoxyalkyl mercury nitrogen compounds
US2673205A (en) 1951-02-13 1954-03-23 Ciba Pharm Prod Inc 3-disubstituted dioxopiperidines and the manufacture thereof
DE946804C (de) 1952-02-28 1956-08-09 Emanuel Merck Ohg Verfahren zur Herstellung von schwefelhaltigen Abkoemmlingen der Barbitursaeure
DE1103339B (de) 1959-02-04 1961-03-30 Chemische Werke Radebeul Veb Verfahren zur Herstellung von in 5-Stellung crotylierten, basisch substituierten Barbitursaeure-derivaten
DE1100639B (de) 1959-03-24 1961-03-02 Chemische Werke Radebeul Veb Verfahren zur Herstellung von basisch substituierten Barbitursaeure-derivaten
GB966098A (en) 1959-11-23 1964-08-06 Sapos Sa Barbiturate derivatives
US4046894A (en) 1968-08-05 1977-09-06 Bristol-Myers Company Certain barbituric acid derivatives used as anticonvulsant agents
US3679683A (en) * 1970-05-11 1972-07-25 Exxon Research Engineering Co Barbiturate 3-n-methylene phosphates
US3711607A (en) 1971-03-17 1973-01-16 Kendall & Co N,n -dihalomethyl phenobarbital for the treatment of convulsions
US3904627A (en) 1972-06-02 1975-09-09 Kendall & Co 1-methyl-3-alkoxymethyl-5,5-disubstituted barbituric acid compounds
US3919427A (en) 1972-06-02 1975-11-11 Kendall & Co Therapeutic compositions containing 1-methyl-3-alkoxymethyl-5,5-disubstituted barbituric acid compounds
US3900475A (en) 1972-06-26 1975-08-19 Kendall & Co Certain phenobarbital salts
US3948896A (en) 1973-02-28 1976-04-06 The Kendall Company N-mono(alkoxymethyl) phenobarbitals, process therefor and therapeutic composition and method containing same
US4060528A (en) 1975-10-08 1977-11-29 Janssen Pharmaceutica N.V. Aroyl-substituted phenylmalonic acid derivatives
US4029662A (en) 1976-04-30 1977-06-14 Bristol-Myers Company Method of making barbituric acid derivatives
DE2622981A1 (de) 1976-05-21 1977-12-08 Unisearch Ltd Verfahren zur herstellung von halogenalkylierten verbindungen
US4260769A (en) * 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
EP0103233B1 (fr) 1982-08-31 1987-11-25 Daikin Kogyo Co., Ltd. Méthode pour attraper l'ion énolate de l'acide malonique ou de ses dérivés
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
US4631294A (en) 1985-07-05 1986-12-23 University E.M., Inc. Treatment of cerebral ischemia with dichloroacetate
IT1196500B (it) 1986-07-16 1988-11-16 Eniricerche Spa Derivati dell'acido malonico e metodi per la loro sintesi
HU196775B (en) 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
US4833148A (en) 1987-04-09 1989-05-23 Washington University Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury
US5474990A (en) 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
DE4028040A1 (de) 1990-09-05 1992-03-12 Chemie Linz Deutschland Verfahren zur n-alkylierung von harnstoffen
US5456851A (en) * 1994-04-07 1995-10-10 Johnson & Johnson Consumer Products, Inc. Ketoconazole shampoo containing butylated hydroxytoluene or butylated hydroxyanisole
DE4433764A1 (de) 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
DE19504623A1 (de) 1995-02-13 1996-08-14 Bayer Ag Verfahren zur Herstellung von N-substituierten cyclischen Imiden
RU2147584C1 (ru) 1995-10-27 2000-04-20 Американ Цианамид Компани Способ получения дигалоидазолопиримидинов и способ получения дигидроксиазолопиримидинов
KR100194535B1 (ko) 1995-12-27 1999-06-15 우종일 아릴 벤조일 우레아 유도체 및 이를 함유하는 농약조성물
EP0949259B1 (fr) 1996-12-26 2001-06-20 Nikken Chemicals Company, Limited Derives de n-hydroxyuree et compositions medicinales a base de ces derives
US5750766A (en) 1997-03-18 1998-05-12 American Cyanamid Company Process for the preparation of arylmalonates
US5756815A (en) 1997-03-18 1998-05-26 American Cyanamid Company Process for the preparation arylamalonates
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
CA2317008C (fr) * 1997-12-31 2009-01-20 The University Of Kansas Remedes contenant des precurseurs hydrosolubles d'amines tertiaires et leurs procedes d'obtention
CA2331735A1 (fr) 1998-05-08 1999-11-18 Smithkline Beecham P.L.C. Derives de phenyluree et de (phenylthio)uree
WO1999061427A1 (fr) 1998-05-26 1999-12-02 Rimma Iliinichna Ashkinazi Derives n-substitues d'acide 5-oxyiminobarbiturique
US6156925A (en) 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
US7214658B2 (en) 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
US6262067B1 (en) 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
US20020004065A1 (en) 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
CA2306170A1 (fr) 2000-04-18 2001-10-18 Kenneth Curry Nouveaux derives amines et carboxyles de l'acide barbiturique
WO2002007729A1 (fr) 2000-07-26 2002-01-31 Taro Pharmaceutical Industries Ltd. Composes de barbiturique non sedatifs en tant qu'agents neuroprotecteurs
US6939873B2 (en) 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
CA2471436C (fr) 2002-01-30 2011-10-11 Taro Pharmaceutical Industries Ltd. Derives d'acide barbiturique non sedatifs
TWI334780B (en) 2002-12-11 2010-12-21 Taro Pharmaceuticals Ireland Ltd Method of treating movement disorders using barbituric acid derivatives
CA2572797A1 (fr) 2004-07-02 2006-01-12 Daniella Gutman Procede de preparation d'acide 1-methoxymethyl-5,5-diphenylbarbiturique
EP1625848A1 (fr) 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition et procédé pour améliorer l'administration de l'acide 5,5-diphénylbarbiturique
EP2081576A4 (fr) 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame Procédé d'amélioration de la biodisponibilité pour les barbituriques non sédatifs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930006A (en) * 1963-04-30 1975-12-30 Aspro Nicholas Ltd Antiparkinsonism compositions and method
WO2001039779A1 (fr) * 1999-12-01 2001-06-07 Ucb, S.A. Derive de pyrrolidine acetamide seul ou combine pour traiter des affections du snc

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BASHIR KHURRAM ET AL: "Clozapine for the control of hemiballismus", CLINICAL NEUROPHARMACOLOGY, vol. 17, no. 5, 1994, pages 477 - 480, XP009032005, ISSN: 0362-5664 *
HAMANN MELANIE ET AL: "Effects of striatal injections of GABAA receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 443, no. 1-3, 17 May 2002 (2002-05-17), pages 59 - 70, XP002284223, ISSN: 0014-2999 *
ONDO W ET AL: "Essential tremor. Treatment options", CNS DRUGS 1996 NEW ZEALAND, vol. 6, no. 3, 1996, pages 178 - 191, XP009032008, ISSN: 1172-7047 *
SASSO E ET AL: "DOUBLE-BLIND COMPARISON OF PRIMIDONE AND PHENOBARBITAL IN ESSENTIAL TREMOR", NEUROLOGY, vol. 38, no. 5, 1988, pages 808 - 810, XP009032012, ISSN: 0028-3878 *
STURFELT G ET AL: "ACUTE EFFECTS OF BARBITURATES IN PARKINSON'S DISEASE", ACTA MEDICA SCANDINAVICA, ALMQVIST & WIKSELL PERIODICAL CO., STOCKHOLM, SE, vol. 201, no. 1/2, 1977, pages 75 - 76, XP000937405, ISSN: 0001-6101 *

Also Published As

Publication number Publication date
US20070072886A1 (en) 2007-03-29
CN100502871C (zh) 2009-06-24
JP2006510659A (ja) 2006-03-30
US8314115B2 (en) 2012-11-20
ATE413867T1 (de) 2008-11-15
TWI334780B (en) 2010-12-21
CA2505335A1 (fr) 2004-06-24
US7166610B2 (en) 2007-01-23
AU2010200787A1 (en) 2010-03-25
ES2315569T3 (es) 2009-04-01
TW200822927A (en) 2008-06-01
AU2003302897C1 (en) 2010-07-08
WO2004052350A2 (fr) 2004-06-24
DE60324703D1 (de) 2008-12-24
US7776871B2 (en) 2010-08-17
AR042444A1 (es) 2005-06-22
US20040186120A1 (en) 2004-09-23
CN101569626A (zh) 2009-11-04
JP4739760B2 (ja) 2011-08-03
EP2156839A1 (fr) 2010-02-24
AU2003302897B2 (en) 2009-12-03
BR0317289A (pt) 2005-11-08
EP1569627A2 (fr) 2005-09-07
TW200418481A (en) 2004-10-01
EP1569627B1 (fr) 2008-11-12
AU2003302897A1 (en) 2004-06-30
CN101569626B (zh) 2012-02-08
PT1569627E (pt) 2009-01-20
US20100311771A1 (en) 2010-12-09
IL168853A (en) 2011-07-31
CL2003002588A1 (es) 2005-01-07
MXPA05006271A (es) 2006-01-30
CA2505335C (fr) 2013-09-10
CN1717235A (zh) 2006-01-04

Similar Documents

Publication Publication Date Title
WO2005056524A3 (fr) Agents therapeutiques pour traitement de la douleur
WO2004056786A3 (fr) Composes pour traiter le developpement anormal de cellules
IL175716A (en) 2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation
MY139357A (en) Novel benzoimidazole derivatives useful as antiproliferative agents
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
SE0104334D0 (sv) Therapeutic agents
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
GEP20084527B (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
WO2004029031A3 (fr) Agents therapeutiques utiles dans le traitement de la douleur
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
WO2005116002A3 (fr) Inhibiteurs de deshydrogenase 1-beta-hydroxy steroide de type 1
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
NZ545506A (en) Therapeutic agents useful for treating pain
PL1664041T3 (pl) Przydatne do leczenia bólu związki fenylowo-karboksyamidowe
DK1556354T3 (da) Terapeutiske piperazinderivater, der er egnede til behandling af smerter
WO2002085861A8 (fr) Composes d'imidazolidine et leur utilisation comme antagonistes de cxcr3
WO2002008219A3 (fr) Nouvelles 2-adamantylethylamines et leur utilisation dans le traitement d'etats generalement associes a des anomalies de la transmission glutamatergique
HK1046405A1 (zh) 作为nmda受体拮抗剂用於治疗疼痛的取代的1，5-二氢吡咯-2-酮衍生物
WO2004052350A3 (fr) Methode de traitement de troubles moteurs a l'aide de derives de l'acide barbiturique
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
WO2002102978A3 (fr) Antagonistes de l'hormone de croissance humaine
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
WO2004041802A8 (fr) Derives de 4(phenyl-piperazinyl-methyl) benzamide et utilisation de ceux-ci pour le traitement de la douleur et des troubles gastro-intestinaux
NO20013409L (no) Anvendelse av pyrimidin-derivater for forhindring og behandling av cerebral ischemi

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2505335

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1990/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 20038A4405X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 168853

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003812970

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/006271

Country of ref document: MX

Ref document number: 2003302897

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004558727

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003812970

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0317289

Country of ref document: BR